Abstract
Context
Chronic Neurological Disorders (CNDs) are among the leading causes of disability worldwide, and their contribution to the overall need for rehabilitation is increasing. Therefore, the identification of new digital solutions to ensure early and continuous care is mandatory.
Objective
This protocol proposes to test the usability, acceptability, safety, and efficacy of Telerehabilitation (TR) protocols with digital and robotic tools in reducing the perceived level of disability in CNDs including Parkinson's Disease (PD), Multiple Sclerosis (MS), and post-stroke patients.
Design, Setting, and Subjects
This single-blinded, multi-site, randomized, two-treatment arms controlled clinical trial will involve PD (N = 30), MS (N = 30), and post-stroke (N = 30). Each participant will be randomized (1:1) to the experimental group (20 sessions of motor telerehabilitation with digital and robotic tools) or the active control group (20 home-based motor rehabilitation sessions according to the usual care treatment). Primary and secondary outcome measures will be obtained at the baseline (T0), post-intervention (T1, 5 weeks after baseline), and at follow-up (T2, 2 months after treatment).
Main Outcome Measures
a multifaceted evaluation including quality of life, motor, and clinical/functional measures will be conducted at each time-point of assessment. The primary outcome measures will be the change in the perceived level of disability as measured by the World Health Organization Disability Assessment Schedule 2.0.
Conclusion
The implementation of TR protocols will enable a more targeted and effective response to the growing need for rehabilitation linked to CNDs, ensuring accessibility to rehabilitation services from the initial stages of the disease.
Keywords
Introduction
According to the Global Burden of Diseases, Injuries, and Risk Factors Study, neurological disorders are one of the major causes of disability in the world, resulting in 276 million disability-adjusted life-years. 1 In particular, Parkinson's disease (PD), Multiple Sclerosis (MS), and post-stroke are among the central chronic neurological disorder (CND) associated with the highest number of years of life lived with disability, resulting in limited daily activities, restrictions in social participation, and poor quality of life. 2
Rehabilitation is relevant to the needs of people with these CNDs and consists of a multimodal, person-centred process with specific interventions targeting body structures, functions, activity/participation, and contextual factors to achieve optimal functioning. 3 To obtain functional and healthy outcomes, early, intensive, and continuous interventions are essential. Rehabilitation should start as soon as possible after the diagnosis of a neurological disorder and must be ensured for a long time after discharge.4,5 However, policymakers and healthcare professionals seem not equipped to deal with the large need for rehabilitation. Rehabilitation services and resources for people with CNDs are limited or lacking in many developing countries, especially in low-income and developing ones. 6 Moreover, as currently provided, rehabilitation interventions are difficult to access for all those in need, especially in the initial stages of the disease. 2 Therefore, the identification of feasible and effective therapeutic solutions becomes essential to expand the offer of rehabilitation services to all those who can benefit from it, along the entire course of the disease.
The current disruptive digital and robotics technological progress represents a valuable resource to increase accessibility to rehabilitation. The use of health technologies and the provision of remote Telerehabilitation (TR) services through digital platforms represent the new frontier for integrated and long-term management of chronic neurological disability.7,8 Previous studies in the field9–18 investigated the feasibility and efficacy of innovative, multidimensional TR approaches. They involved new digital solutions to ensure early and continuous management of CNDs, including PD and MS, beyond the hospital walls. The principal goal was to provide patients, families, and clinicians with instruments that are clinically validated, safe, easily accessible, and usable. Moreover, robot-based treatments are developing in neurorehabilitation settings. Robot-assisted rehabilitation has proven to be effective in improving both motor 19 and cognitive 20 functions in CNDs. The use of robotic tools allows providing for more intense and controlled training within a highly personalized therapeutic plan. 21 Moreover, robotic rehabilitation tools can promote the best recovery of sensorimotor, behavioral, and motor functionalities according to the individual functional profile of each patient.22–28 Robotic solutions are commonly adopted in clinics but also at the patient's home to assure the continuity of care for stroke patients. In fact, a further challenge the neurorehabilitation concerns the need to “rethink the patient's home as a place of care”. 29
In this framework, rehabilitation interventions delivered with digital and robotics solutions are ideal candidates, but just like the new drugs, these digital medical solutions will require a rigorous evidence-based approach. 8 Starting from these premises, this project will aim to evaluate the usability, acceptability, safety, and efficacy of TR protocols with digital and robotic tools in reducing the perceived level of disability in persons with CNDs using a Randomized Controlled Trial (RCT) design.
Materials and methods
The protocol of the study has been conceived as outlined in the “Standard Protocol Items: Recommendations for Interventional Trials” (SPIRIT) guidelines (Figure 1). The study will be conducted according to the Declaration of Helsinki, the principles of Good Clinical Practice, and in accordance with local legislation in participating countries.

SPIRIT figure for the schedule of enrolment, interventions, and assessments in a parallel arm study design. T0 = baseline (pre-intervention phase); T1 = post-treatment assessment; T2 = follow-up assessment (8 weeks after the end of the treatment). WHODAS 2.0: WHO Disability Assessment Schedule 2.0; EDSS: Expanded Disability Status Scale; MDS-UPDRS: Movement Disorder Society - Unified Parkinson's Disease Rating Scale; FMA-UL: Fugl-Meyer Assessment – Upper Extremity; ARAT: Action Research Arm Test; BBT: Box and Block Test; 9-HPT: Nine Hole Peg Test; mDGI: modified Dynamic Gait Index; Mini-BESTest: Mini-Balance Evaluation Systems Test; ABC: Activities Balance Confidence scale; MoCA: Montreal Cognitive Assessment test; TMT: Trail Making Test; SDMT: Symbol Digit Modalities Test; BDI-PC: Beck Depression Inventory for Primary Care; STAI-Y2: State-Trait Anxiety Inventory – Form Y2; MRI: Magnetic Resonance Imaging; SUS: System Usability Scale; TAM: Technology Acceptance Model. #Optional evaluation.
Trial design and setting
This study is designed as a single-blinded, randomized, two-treatment arms controlled clinical trial involving chronic outpatients from neurorehabilitation units of IRCCS Fondazione Don Carlo Gnocchi (Milan and Rome, Italy). After the enrolment and baseline assessment, each participant will be randomized (with an allocation ratio of 1:1) to the experimental group (20 sessions of motor TR with digital and robotic tools) or the active control group (20 motor rehabilitation sessions performed at home according to the usual care treatment procedure). Randomization will be stratified according to CNDs. Primary and secondary outcome measures will be obtained at the baseline (T0), post-intervention (T1, 5 weeks after baseline), and at follow-up (T2, 8 weeks after the end of the treatment). The trial work plan is shown in Figure 2.

The trial work plan.
Sample size
According to an a-priori sample size calculation (using the G*Power software,30,31) 90 subjects (45 subjects per arm), comprehensive of up to 10% drop-off, is sufficient to detect a medium to large standardized effect size (0.695) when considering the independent comparison between two groups (two-sided unpaired t-test). The Effect size was obtained from our previous unpublished study that compared two groups of treatments in WHODAS 2.0 32 total score (TR group mean = -2.91 ± 8.61; UC group mean = 3.31 ± 9.26) and was chosen as a benchmark as the studies are similar in terms of methods and materials. Power calculation was conducted considering a type-I error rate of 5% (α = 0.05) with a statistical power of 0.80.
Study population, recruitment, and randomization
According to the sample size calculation, this trial has a recruitment target of 90 CND individuals with the diagnosis of post-Stroke (N = 30), PD (N = 30), and MS (N = 30). Eligible patients who meet all inclusion criteria (see the paragraph below) will be randomized using a web-based allocation concealment through a computer-based algorithm created by an independent statistician. We will adopt a stratified randomization to prevent imbalance between treatment groups. The sample will be stratified according to the clinical condition (SM, PD, post-stroke) and randomly allocated (1:1) into either the experimental group or the active control group. The trial intervention will not be blinded for clinicians or patients due to its nature. Conversely, clinical endpoints and data collection from clinical/psychological questionnaires will be blinded to examiners/assessors. The statistician conducting the data analysis will be masked for the group allocation.
Inclusion and exclusion criteria
The inclusion criteria for all participants will be:
diagnosis of chronic post-stroke condition with ischemic or haemorrhagic stroke injury occurred 4–6 months before recruitment and with motor impairment of the upper limb > 2 to the Medical Research Council scale (MRC);
or
diagnosis of probable PD according to MDS criteria 33 in staging between 1.5 and 3 on the Hoehn & Yahr scale 34 ;
or
diagnosis of MS, RR-SP forms, according to the criteria of MC Donald 2010
35
with disability level at the Expanded Disability Status Scale EDSS
36
< 6
age between 25 and 85 years; preserved cognitive level at the Montreal Cognitive Assessment test (MoCA test >17.36)
37
; agreement to participate with the signature of the informed consent form; no rehabilitation program in place at the time of enrolment; stable drug treatment (last 3 months) with L-Dopa or dopamine agonists (PD group) and/or cortisone (MS group). presence of comorbidities that might prevent patients from undertaking a safe home program or determining clinical instability (i.e., severe orthopedic or severe cognitive deficits); presence of major psychiatric complications or personality disorders; presence of severe impairment of visual and/or acoustic perception; relapse ongoing/at least 3 months since the last relapse (MS group); presence of “frequent” freezing as recorded at the administration of Section II (daily life activity) of the UPDRS (score ≥ 3) (PD group); falls resulting in injuries or more than 2 falls in the 6 months prior to recruitment (PD and MS groups).
The exclusion criteria for all participants will be:
Trial interventions
The Trial protocol provides for the random allocation of participants to two different types of rehabilitation treatment: Telerehabilitation treatment (TR) and Usual Care (UC), according to a single-blind, parallel arm design.
Frequency: the TR group will experience 5 weeks (4 sessions/week) of TR intervention provided according to a mixed model (3 asynchronous sessions + 1 synchronous, in-clinic session/week). Participants will freely choose when to perform each home TR-session according to their preferences and needs; Intensity: each session will be customized according to the patient's functional abilities to ensure the progression of difficulty in rehabilitation sessions (system's feedback); Time: each session will last about 50 min/day; Type: according to the disease, patients will perform TR protocols with a digital system (TR Type A for MS and PD) or robotic tool (TR Type B for post-stroke).
Examples of task-oriented activities. CoM = Centre of Mass.
Outcome measures
Participants will undergo an extensive evaluation at the baseline (T0), post-intervention (T1), and at the follow-up (T2) (see Figure 1 “Study Period”).
Primary outcome measure
The primary outcome will be the change in the perceived level of disability as measured by the World Health Organization Disability Assessment Schedule 2.0 (
Secondary outcome measures
Secondary outcomes will be the changes in cognitive and motor measures evaluated at each time point of evaluation (T0, T1, and T2).
Outcome measures common to all rehabilitation scenarios (PD, MS, and post-stroke)
The global cognitive functioning will be evaluated in PD, MS, and post-stroke groups through the
As specific measures of visuo-perceptual and attentional abilities, the
The TMT is a neuropsychological test that involves visual scanning (TMT-A) and dual-task (TMT-B). In Part A, the participant must draw a line to connect consecutive numbers from 1 to 25. In Part B, the participant connects numbers and letters in an alternating progressive sequence, 1 to A, A to 2, 2 to B, and so on. The TMT is scored by how long it takes to complete each part of the test. Moreover, in order to measure executive functioning, the difference in time between TMT-B and TMT-A is calculated (TMT B-A). High execution times indicate poor performance.
The SDMT is a commonly used test to assess psychomotor speed. This paper-pencil measure involves a substitution task using a coding key with nine different abstract symbols, each paired with a numeral. Below the key, a series of these symbols is presented, and the participant is asked to write down the corresponding number for each symbol. The score consists of the number of correct substitutions within 90 s. Higher scores indicate better performance.
The
The BDI-PC is a 7-item questionnaire with each item rated on a 4-point scale (0–3). It is scored by summing ratings for each item (range 0–21). Higher scores indicate greater deflection of mood tone.
The STAI-Y is a commonly used measure of trait and state anxiety (20 items for each). All items are rated on a 4-point scale (from “Almost Never” to “Almost Always”). STAI – Y2 is scored by summing ratings for each item (State-Anxiety: range 0–80; Trait Anxiety: range 0–80). Higher scores indicate greater anxiety.
As a measure of gross manual dexterity, the
Outcome measures common to PD and MS groups
The finger dexterity will be measured by the
The
The Mini-BESTest aims to identify the disordered systems underlying the postural control responsible for poor functional balance. This tool is composed of 27 tasks (36 items in total) assessing biomechanical constraints, stability limits/verticality, anticipatory responses, postural responses, sensory orientation, and stability in gait. Each item is scored based on ordinal scale scoring from 0 to 3 where 3 = best performances and 0 = worst performances. The total score is provided as a percentage. Higher scores are indicative of better performance.
Changes in the perceived stability during activities of daily living will be measured with the
Outcome measures specific for MP, SM, or post-stroke group
The
The
The
The ARAT is a 19-item measure assessing the upper extremity performance (coordination, dexterity, and functioning). Items are scored using a 4-point ordinal scale where 0 = “no movement”, 1= “movement task is partially performed”, 2 = “movement task is completed but takes abnormally long”, and 3 = “movement is performed normally”. Scores range from 0 to 57 points with higher scores indicating better performance.
Other outcomes
Brain
Data collection
Demographic characteristics and the level of the technological expertise of patients will be collected at the baseline evaluation (T0); data from participation, clinical, functional, and motor measures (primary and secondary outcomes) will be collected by blinded examiners/assessors at each time-point of evaluation (T0, T1, T2); to ensure that patients follow the prescribed intervention, paper diaries will be used in the UC group to record the date of execution, the number of exercises performed, the time spent, and any difficulties encountered during the exercise training. In contrast, the TR group will have their adherence automatically collected through the digital platform; finally, data on the usability and acceptability of the technological solutions and safety of interventions will also be collected post-intervention (T1). Specifically, the technological systems usability will be evaluated with the System Usability Scale (
Statistical analysis
Statistical analyses on outcome measures will be conducted using Jamovi 2.2 69 (https://www.jamovi.org). Descriptive statistics of the sample will include frequencies for categorical data, median and interquartile range (IQR) for ordinal variables, and Mean and Standard Deviation (SD) for continuous measures. The assumption of normality will be checked by the Shapiro-Wilk test for continuous variables. We will investigate statistically significant after-treatment changes in primary and secondary outcome measures according to the Consolidated Standards of Reporting Trials (CONSORT) guidelines. An Intention-to-treat approach will be carried out to address missing data. A treatment effect (TR vs. UC) will be investigated through repeated measures ANOVA. Moreover, a score modification at follow-up (T2, 2 months after treatment) in both groups will be evaluated by means of regression analyses over time considering previous values at baseline and T1.
Discussion
The increasing demand for rehabilitation among people with neurological conditions claims the identification of innovative digital solutions able to enhance access to rehabilitation services while promoting quality-of-life, clinical, and functional outcomes. Results from the present RCT will inform about the usability, acceptability, safety, and efficacy of TR protocols with digital (Homing) and robotic (iCONE) tools in reducing the perceived level of disability in post-stroke, PD, and MS patients.
The reason for choosing Homing and iCONE (“pros”) is that they are designed to enhance an intensive rehabilitation program with task-oriented exercises. The task-oriented training is a well-known rehabilitation approach that can have a positive impact on recovery by enhancing brain plasticity after brain injury or neurodegeneration. Moreover, intensive multisensory rehabilitation is particularly effective, but it requires a high level of commitment from both patients and physiotherapists, resulting in high costs for the healthcare system.
Overcoming these obstacles to rehabilitation can be challenging, but these two systems offer ways to help. iCONE and Homing systems allow for controlled and customized task-oriented exercises based on the unique characteristics of each patient at home. Screens and visual/auditory feedback provide sensory input, promoting learning and engagement through the interactive nature of the technological device. Furthermore, both iCONE and Homing are cloud-based systems, allowing the clinical staff to manage remotely the rehabilitation intervention. Finally, these technological systems are ease transportable, permitting their use across various settings including the patients’ home or other non-hospital environments. It's worth highlighting that one of the major “cons” of telerehabilitation could be represented by the inability of the therapist to act in case of symptoms and adverse events and providing the patients with some home-based solutions to monitor vital parameters during the rehabilitation protocol could be important to promote safety during the telerehabilitation session (and after it). Future steps of development could integrate the system with digital devices for telemonitoring.
We expect that TR protocols will be both usable and acceptable for people with CNDs in line with previous data.10,17,18,22 It is well known that TR can serve as a powerful tool to strengthen rehabilitation in primary health care increasing access to care and overcoming barriers. TR has proven to be useful and effective for patients with NCD during the lockdown period due to the SARS-CoV-2 pandemic but should become a constant asset to ensure continuity of care from the clinic to the patient's home. 70 The adoption of digital and robotic technologies within the TR approach will allow for overcoming accessibility and cost barriers and scaling up rehabilitation services to patients in need from the early stages of the disease.
The flexibility that characterizes TR protocols will allow people with CNDs to freely choose when to complete each daily rehabilitation session in relation to their preferences and daily needs and routines. This option increases the engagement and compliance of patients, promoting the achievement of health and quality of life outcomes. 71
In addition, we expect that the TR approach will determine several positive effects on quality of life, reducing the perceived level of disability. Our previous studies in the field showed that the TR approach with digital or robotic tools ensured the continuity of care in people with CNDs, with high levels of adherence to treatment,10,11,13,17 short- and long-term beneficial effects on both motor and non-motor abilities,11,13,17,19,20,23,28 and improved quality of life domains such as participation and autonomy in daily routine.10,11,13,17,19,23
This study is not without limitations. We recognize that technical problems such as the lack of internet connectivity and insufficient space for motor exercises at home may hinder the availability of TR treatment. Additionally, the follow-up evaluation period is relatively short due to study constraints.
Conclusion
The implementation of TR protocols with robotics and digital tools, developed and validated with an evidence-based approach, will enable a more targeted and effective response to the growing need for rehabilitation linked to chronic neurological conditions. We expect that the flexibility that characterizes the TR protocols will promote the motivation and engagement of patients in their continuum of care, enhancing adherence to treatment and the achievement of health and quality-of-life outcomes. Future steps of implementation could integrate the technological platform with digital devices for telemonitoring. This will enable real-time tracking of vital parameters (e.g., blood pressure and heart rate) for each patient, along with performance data and treatment adherence. Such integration will allow for better monitoring of safety during the rehabilitation sessions.72,73
Supplemental Material
sj-docx-1-dhj-10.1177_20552076241228928 - Supplemental material for Efficacy of telerehabilitation with digital and robotic tools for the continuity of care of people with chronic neurological disorders: The TELENEURO@REHAB protocol for a randomized controlled trial
Supplemental material, sj-docx-1-dhj-10.1177_20552076241228928 for Efficacy of telerehabilitation with digital and robotic tools for the continuity of care of people with chronic neurological disorders: The TELENEURO@REHAB protocol for a randomized controlled trial by Federica Rossetto, Fabiola Giovanna Mestanza Mattos, Elisa Gervasoni, Marco Germanotta, Arianna Pavan, Davide Cattaneo, Irene Aprile and Francesca Baglio in DIGITAL HEALTH
Footnotes
Acknowledgements
We acknowledge the “Ico Falck Foundation” for the financial support.
Contributorship
Conceptualization of the work: FB, IA, DC and FR; writing original draft: FR, FB, FGMM, MG; review and editing: FGMM, EG, MG, and AP; All authors approved of the final version of the manuscript.
Declaration of conflicting interests
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Ethical approval
The study was approved by the Ethical Committee of IRCCS Fondazione Don Carlo Gnocchi and was registered as a clinical trial on clinicaltrials.gov (identifier NCT06009770). Prospective participants will be fully informed of the aims and procedures of the project. A reporting procedure will be in place to ensure that any serious adverse events are reported to the Chief Investigator. Informed written consent will be obtained from all participants before the study initiation.
Funding
This study is supported by Ico Falck Foundation (Milan) within the project named TELENEURO@REHAB.
Patient-Centered Outcomes Research Institute (grant number MS-1610-37015-Enhancement).
Guarantor
FR.
Supplemental material
Supplemental material for this article is available online.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
